Description
Market Report, 220 Pages
August 2025
For a limited time, you can claim this report for an unusual $500 off. Act fast, because this offer expires soon.
CAR-T industry funding isn’t gaining traction, it is surging. At first, the trend was subtle, but the tide has swelled as CAR-T therapies have reached the marketplace and created a funding boom. Today, CAR-T start-ups are being richly funded by investors and large pharma who are eager to get into this trending area of regenerative medicine.
Worldwide, more than 170 companies are now developing CAR-T products and therapies, with a total of 1,944 early and late-stage therapies in development. These companies have also entered into 110 collaboration agreements aimed at advancing various CAR-T candidates. Of these, only 38 have disclosed the value of their deals, which amounts to $23.58 billion. If we estimate the value of the undisclosed deals, the total value of these 110 collaborations is likely to reach approximately $67.9 billion.
The clinical successes of CAR-T therapies have sparked significant interest from venture capitalists globally. This increased activity has fueled advancements in CAR-T technology and the development of applications for both hematological cancers and other types of cancer. Since 2014, a total of 89 CAR-T companies have secured $7.7 billion in venture capital, enabling them to strengthen their foundations. Venture capital funding has remained strong and consistent throughout the development of the CAR-T industry.
Data shows that Initial Public Offerings (IPOs) within the CAR-T space were relatively slow last year. In 2024, only Kyverna Therapeutics went public, raising $319 million to support its anti-CD19 CAR-T therapies. However, from January 2014 to February 15, 2025, 42 CAR-T companies went public, collectively raising $6.4 billion to further enhance their technology platforms, clinical trials, and corporate strategies.
Within this rapidly evolving industry, there are currently 72,418 patent records and 452 granted patents. As a result, large pharmaceutical companies are increasingly seeking to enter the CAR-T market by licensing patents from existing patent holders. Over the past decade, 91 CAR-T licensing deals have been valued at $6.3 billion, and this figure is expected to grow significantly over the next ten years.
While 2023 saw a resurgence in dealmaking, the CAR-T industry experienced a slowdown in mergers and acquisitions (M&A) in 2024, with only two deals completed. Although major M&A activity may not return in 2025, further deals are likely as large pharmaceutical companies look to deploy their cash reserves. Over the past decade, M&A deals have accounted for the largest share of CAR-T industry financing, totaling an impressive $97.4 billion.
In total, the CAR-T industry has raised more than $141.2 billion through various deal types, including IPOs, licensing deals, collaborations, and M&A transactions. It’s important to note that the values of 61 out of 91 licensing deals, 75 out of 110 collaboration deals, and 12 out of 29 M&A deals remain undisclosed. If we estimate the value of these undisclosed transactions, the overall total is likely to reach a staggering $281.7 billion.
Globally Approved CAR-T Therapies
Scientific progress within the field of cancer immunotherapy has led to 13 CAR-T cell therapy approvals globally. While Relma-cel, Yuanruida, Fucaso and Zevor-cel have been approved by NMPA in China, NexCAR19 and Qartemi have been approved in India. The remaining seven therapies were approved by the U.S. FDA, after which approvals for them were issued in other major healthcare markets as well. The 13 products include:
- Kymriah (tisagenlecleucel) – US FDA
- Yescarta (axicabtagene ciloleucel) – US FDA
- Tecartus (brexucabtagene autoleucel) – US FDA
- Breyanzi (lisocabtagene maraleucel) – US FDA
- Abecma (idecabtagene vicleucel) – US FDA
- Relma-cel (relmacabtagene autoleucel) – NMPA China
- Carvykti (ciltacabtagene autoleucel) – US FDA
- NexCAR19 (actalycabtagene autoleucel) – CDSCO India
- Yuanruida (inaticabtagene autoleucel) – NMPA China
- Qartemi (varnimcabtagene autoleucel) – CDSCO India
- Aucatzyl (obecabtagene autoleucel) – US FDA
- Fucaso (equecabtagene autoleucel) – NMPA China
- Zevor-cel (zevorcabtagene autoleucel) – NMPA China
All 13 approved CAR-T cell therapies are currently used exclusively to treat blood cancers, which account for less than 5% of cancer patients worldwide. As of February 18, 2025, there are approximately 1,944 ongoing clinical trials (up from 1,881 trials in December 2024) focused on addressing both blood cancers and solid tumors. Of these, only 244 trials are targeting solid cancers. This increase in the number of clinical trials has been driven by the remarkable 90% remission rate achieved by most of the approved CAR-T therapies.
To summarize, there have been hundreds of billions of dollars in financial transactions completed by CAR-T companies in recent years. Ranging from small start-ups to billion-dollar companies, CAR-T companies are proliferating in all healthcare markets worldwide.
CAR-T Market Overview
To track these industry events, BioInformant released this 220 page CAR-T market funding report. It summarizes all types of investments flowing into CAR-T companies worldwide, including financing rounds, IPOs, M&A transactions, co-development agreements, and strategic partnerships. Additionally, it profiles 78 leading competitors who have been involved with these CAR-T industry funding events.
It features the following information for the CAR-T cell therapy industry:
- Financing Rounds
- IPOs
- Asset Agreements
- Strategic Partnerships
- Co-Development Agreements
- M&A Transactions
- Companies Profiles for CAR-T Market Competitors
Use it to:
- Quantify CAR-T industry investments
- Identify well-capitalized companies
- Scout potential partnerships and alliances
- Understand partnerships and co-development programs for CAR-T technologies
- Identify M&A activity within the CAR-T industry
TABLE OF CONTENTS: Global CAR-T Funding Report – Venture Capital, IPOs, Licensing Deals, Collaborations, and M&A Transactions, 2025
This research was originally compiled for our internal use, but many of BioInformant’s clients were requesting access to it.
Would you benefit from accessing all known CAR-T cell therapy funding events worldwide? If so, you can claim this report below and your order will be available for immediate download with printing rights allowed.
About BioInformant
With an online readership of nearly one million viewers per year, BioInformant is a U.S. market research firm with 18+ years of experience. As the first and only market research firm to specialize in the cell therapy industry, BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine. Headquartered near Washington, DC, BioInformant is strategically positioned to be near the National Institutes of Health (NIH), U.S. FDA, Maryland Biotech Corridor, and policy makers on Capitol Hill. Serving all-star clients that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in cell therapy industry data. For more information, read Client Testimonials here.
